-
Disease progression reflected by blood protein signature: Study
Researchers identified a unique protein signature in the bloodstreams of adults with Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD) that significantly differs from healthy individuals after exercise. “We propose that a subset of circulating proteins may be more indicative of disease progression and/or therapeutic efficacy than relying solely on muscle injury biomarkers such…
-
Quest Podcast: Service Dogs, Inc. – Paws with a Purpose
In this Quest Podcast episode, we chat with a former attorney who left her law practice to devote her time to building Service Dogs, Inc. Sheri Soltes founded Service Dogs, Inc. in 1988 on the concept of using dogs rescued from animal shelters. Under her guidance, Service Dogs, Inc. has led the industry in combining…
-
With summer’s hardships come adventures in appreciation
Summer is a great time to be outside, travel, attend neighborhood gatherings, and spend time with people you love. But those of us who live our adult lives with chronic illness face challenges in this season, as well as year-round. Still, there are many ways for us to enjoy the warm weather and continue to…
-
Simpler, Safer Transfers: Helpful Tips and Useful Equipment
Theresa Berner is an occupational therapist. Transferring from one spot to another, such as from a bed to a wheelchair and from a wheelchair to a toilet, can be a daily challenge for those living with neuromuscular diseases. Whether at home or out and about, being able to transfer easily, safely, and comfortably is a…
-
Webinar Recording: Edgewise Therapeutics – Update on Sevasemten Program in Becker and Duchenne
Edgewise Therapeutics recently joined PPMD for a community webinar for an update on the company’s sevasemten program in Duchenne and Becker. The Edgewise team reviewed new Open-label Extension MESA data in Becker, as well as interim data from the ongoing LYNX and FOX Phase 2 studies. Watch the recording The post Webinar Recording: Edgewise Therapeutics…
-
Ifetroban continues to show cardiac protection in Phase 2 DMD trial
Ifetroban, Cumberland Pharmaceuticals’ investigational oral therapy, improved heart function and reduced cardiac damage biomarkers in people with Duchenne muscular dystrophy (DMD), according to new trial data. These findings from the Phase 2 FIGHT DMD trial (NCT03340675) were presented at the Parent Project Muscular Dystrophy (PPMD) annual conference, held recently in Las Vegas. Long-term safety and…
-
Craft Your Story
Crafting Your Story for Awareness, Connection, and Change Webinar. Watch HERE The post Craft Your Story appeared first on CureDuchenne.
